{"id":344156,"date":"2014-11-26T01:00:00","date_gmt":"2014-11-26T00:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/new-standard-in-the-second-line\/"},"modified":"2014-11-26T01:00:00","modified_gmt":"2014-11-26T00:00:00","slug":"new-standard-in-the-second-line","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/new-standard-in-the-second-line\/","title":{"rendered":"New standard in the second line?"},"content":{"rendered":"<p><strong>Drugs that are well established in first-line advanced gastric cancer continue to achieve relatively poor survival prognoses in second-line settings. A new study (RAINBOW) now demonstrates the efficacy of ramucirumab plus paclitaxel in this population. Monotherapy had also already shown a survival benefit, leading to approval in the United States in April.<\/strong><\/p>\n<p> <!--more--> <\/p>\n<p><em>(ag) <\/em>It is clear that VEGFR-2 plays a significant role in the progression and pathogenesis of gastric cancer. This is where the VEGFR2 antagonist ramucirumab comes in: In combination with paclitaxel, it showed a significant improvement in overall survival in pretreated patients in RAINBOW.<\/p>\n<h2 id=\"170-centers-27-countries-665-patients\">170 centers, 27 countries, 665 patients<\/h2>\n<p>The study, which involved nearly thirty countries and a full 170 centers, included 665 pretreated adults with advanced gastric adenocarcinoma (and also those with adenocarcinoma of the gastroesophageal junction). They received either ramucirumab plus paclitaxel (8 mg\/kg, n=330) or placebo plus paclitaxel (n=335).<\/p>\n<h2 id=\"clear-benefit\">Clear benefit<\/h2>\n<p>The primary endpoint, overall survival, showed a significant prolongation in the ramucirumab group (median 9.6 vs. 7.4 months, HR 0.807, p=0.017). Major adverse events of grade three or higher that occurred more frequently in the ramucirumab group were neutropenia (41 vs. 19%), leukopenia (17 vs. 7%), hypertension (14 vs. 2%), fatigue (12 vs. 5%), and abdominal pain (6 vs. 3%). Febrile neutropenias of grade 3 or higher were rare in both groups (3 vs. 2%).<\/p>\n<p>The authors concluded that ramucirumab plus paclitaxel was thus warranted as a new standard of care in the second-line treatment of patients with advanced gastric cancer.<\/p>\n<p><em>Source: Wilke H, et al: The Lancet Oncology 2014; 15(11): 1224-1235.<\/em><\/p>\n<p><em>InFo ONCOLOGY &amp; HEMATOLOGY 2014; 2(9): 6.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Drugs that are well established in first-line advanced gastric cancer continue to achieve relatively poor survival prognoses in second-line settings. A new study (RAINBOW) now demonstrates the efficacy of ramucirumab&hellip;<\/p>\n","protected":false},"author":7,"featured_media":47874,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"RAINBOW Study","footnotes":""},"category":[11391,11370,11548,11503],"tags":[34560,49460,15386,49468],"powerkit_post_featured":[],"class_list":["post-344156","post","type-post","status-publish","format-standard","has-post-thumbnail","category-gastroenterology-and-hepatology","category-oncology","category-rx-en","category-studies","tag-paclitaxel-en","tag-rainbow-study","tag-stomach-cancer","tag-vegfr2-antagonist-en","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-05 12:16:30","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":344167,"slug":"un-nouveau-standard-pour-la-deuxieme-ligne","post_title":"Un nouveau standard pour la deuxi\u00e8me ligne ?","href":"https:\/\/medizinonline.com\/fr\/un-nouveau-standard-pour-la-deuxieme-ligne\/"},"it_IT":{"locale":"it_IT","id":344177,"slug":"nuovo-standard-nella-seconda-linea","post_title":"Nuovo standard nella seconda linea?","href":"https:\/\/medizinonline.com\/it\/nuovo-standard-nella-seconda-linea\/"},"pt_PT":{"locale":"pt_PT","id":344183,"slug":"novo-padrao-na-segunda-linha","post_title":"Novo padr\u00e3o na segunda linha?","href":"https:\/\/medizinonline.com\/pt-pt\/novo-padrao-na-segunda-linha\/"},"es_ES":{"locale":"es_ES","id":344188,"slug":"nueva-norma-en-la-segunda-linea","post_title":"\u00bfNueva norma en la segunda l\u00ednea?","href":"https:\/\/medizinonline.com\/es\/nueva-norma-en-la-segunda-linea\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/344156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=344156"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/344156\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/47874"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=344156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=344156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=344156"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=344156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}